AR047469A1 - Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas - Google Patents

Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas

Info

Publication number
AR047469A1
AR047469A1 ARP050100283A ARP050100283A AR047469A1 AR 047469 A1 AR047469 A1 AR 047469A1 AR P050100283 A ARP050100283 A AR P050100283A AR P050100283 A ARP050100283 A AR P050100283A AR 047469 A1 AR047469 A1 AR 047469A1
Authority
AR
Argentina
Prior art keywords
preservants
cyclodextrines
antimicrobial
beta
achieve
Prior art date
Application number
ARP050100283A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR047469A1 publication Critical patent/AR047469A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente se refiere a composiciones farmacéuticas que contienen una cantidad terapéuticamente eficaz de un ingrediente farmacéuticamente activo (ôAPIö), una ciclodextrina farmacéuticamente aceptable y un conservante farmacéuticamente aceptable. La presente también se refiere a composiciones farmacéuticas de los compuestos de formula (1), en la que R2 se selecciona entre el grupo constituido por metilo, etilo, isopropilo, sec-butilo, y terc-butilo y una ciclodextrina y conservante farmacéuticamente aceptables. Procedimiento para el tratamiento de una enfermedad para la que está indicado un antagonista de los receptores de neuroquinina en mamíferos.
ARP050100283A 2004-01-30 2005-01-27 Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas AR047469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54089704P 2004-01-30 2004-01-30

Publications (1)

Publication Number Publication Date
AR047469A1 true AR047469A1 (es) 2006-01-18

Family

ID=34910697

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050100283A AR047469A1 (es) 2004-01-30 2005-01-27 Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas
ARP170102291A AR109357A2 (es) 2004-01-30 2017-08-16 Composición farmacéutica parenteral con tolerancia en el sitio de inyección

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102291A AR109357A2 (es) 2004-01-30 2017-08-16 Composición farmacéutica parenteral con tolerancia en el sitio de inyección

Country Status (25)

Country Link
US (1) US8183230B2 (es)
EP (1) EP1713504B1 (es)
JP (1) JP5021318B2 (es)
KR (1) KR100834232B1 (es)
CN (1) CN101090735A (es)
AR (2) AR047469A1 (es)
AU (1) AU2005216709B2 (es)
BR (1) BRPI0506496B8 (es)
CA (1) CA2554346C (es)
CO (1) CO5700794A2 (es)
CY (1) CY1119188T1 (es)
DK (1) DK1713504T3 (es)
ES (1) ES2638113T3 (es)
HU (1) HUE034099T2 (es)
IL (1) IL176676A0 (es)
LT (1) LT1713504T (es)
NO (1) NO20063858L (es)
NZ (1) NZ548236A (es)
PL (1) PL1713504T3 (es)
PT (1) PT1713504T (es)
RU (1) RU2332997C2 (es)
SI (1) SI1713504T1 (es)
TW (1) TW200524632A (es)
WO (1) WO2005082416A2 (es)
ZA (1) ZA200605148B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
EP3446692A1 (en) * 2011-11-29 2019-02-27 Jurox Pty. Ltd. Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
ES2860526T3 (es) * 2013-07-19 2021-10-05 Boehringer Ingelheim Vetmedica Gmbh Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
KR20200002899A (ko) 2017-04-10 2020-01-08 체이스 테라퓨틱스 코포레이션 시누클레인병변을 치료하기 위한 nk1-길항제 배합물 및 방법
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
EP3923916A4 (en) * 2019-02-15 2022-12-21 Saol International Development Ltd. INJECTABLE PHENOL FORMULATIONS AND METHODS OF USE
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS59152320A (ja) 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
DK0668863T3 (da) * 1992-11-12 1997-06-30 Pfizer Quinuclidinderivat som substans P-antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
WO2001001955A1 (en) * 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN
HUP0401154A2 (hu) * 2001-07-20 2004-10-28 Pfizer Products Inc. NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására
JP2005521691A (ja) 2002-02-22 2005-07-21 ファルマシア・コーポレーション シクロデキストリン化合物及び塩化セチルピリジニウムを含有する眼科用抗菌性薬物製剤
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
AU2005216706B2 (en) 2004-01-30 2007-11-29 Pfizer Products Inc. NK-1 receptor antagonists anesthesia recovery
AU2005216707A1 (en) 2004-01-30 2005-09-09 Pfizer Products Inc. Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
US20090099364A1 (en) 2004-02-02 2009-04-16 Pfizer Inc. Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine

Also Published As

Publication number Publication date
BRPI0506496A8 (pt) 2017-11-14
AU2005216709B2 (en) 2008-02-07
JP2007519703A (ja) 2007-07-19
JP5021318B2 (ja) 2012-09-05
BRPI0506496A (pt) 2007-02-13
AR109357A2 (es) 2018-11-21
CO5700794A2 (es) 2006-11-30
WO2005082416A2 (en) 2005-09-09
BRPI0506496B1 (pt) 2018-10-09
TW200524632A (en) 2005-08-01
US8183230B2 (en) 2012-05-22
CY1119188T1 (el) 2018-02-14
RU2006127422A (ru) 2008-03-10
WO2005082416A3 (en) 2006-07-27
ES2638113T3 (es) 2017-10-18
IL176676A0 (en) 2006-10-31
BRPI0506496B8 (pt) 2022-09-20
EP1713504A2 (en) 2006-10-25
SI1713504T1 (sl) 2017-10-30
PL1713504T3 (pl) 2017-12-29
CA2554346C (en) 2009-11-17
NO20063858L (no) 2006-10-19
RU2332997C2 (ru) 2008-09-10
US20070155697A1 (en) 2007-07-05
KR100834232B1 (ko) 2008-05-30
ZA200605148B (en) 2007-10-31
AU2005216709A1 (en) 2005-09-09
LT1713504T (lt) 2017-09-11
EP1713504B1 (en) 2017-06-07
CA2554346A1 (en) 2005-09-09
NZ548236A (en) 2010-02-26
KR20060128973A (ko) 2006-12-14
PT1713504T (pt) 2017-08-29
CN101090735A (zh) 2007-12-19
HUE034099T2 (en) 2018-01-29
DK1713504T3 (en) 2017-08-07

Similar Documents

Publication Publication Date Title
AR047469A1 (es) Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
ECSP109905A (es) Moduladores de receptor 7 tipo toll
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
AR059501A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
AR058619A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR033390A1 (es) Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
JP2007008893A (ja) 抗真菌医薬組成物
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
PA8579701A1 (es) Profarmaco inhibidor de beta-lactamasa

Legal Events

Date Code Title Description
FC Refusal